Lupin Limited (NSE: LUPIN), a major pharmaceutical company, has acquired the final approval from the United States FDA for its Oxycodone Hydrochloride tablets. These tablets will be used to treat patients suffering from severe pain.

The Mumbai-based company stated in a report that they had received approval from the US FDA to retail its Oxycodone Hydrochloride tablets USP in 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg strengths. Lupin further added that these tablets are a version of Roxicodone tablets developed by Mallinckrodt Inc.

According to Lupin, these tablets are for pain management but only if the pain is severe enough to need an opioid analgesic as alternative treatment methods are not feasible.

Currently, Lupin has 151 product filings awaiting approval from the US FDA and the company’s shares were trading 0.67% higher at Rs 1,185.25 per scrip on BSE on June 14.

Featured Image: twitter

Author Caroline Harris

About the author: Caroline Harris is a third-year student at Capilano University in North Vancouver, Canada. Having already completed an Associates Degree in Psychology, Caroline is now finishing her Bachelor's degree in Communications. In preparation for working in the advertisement sector, Caroline is writing financial content and analysis. On a daily basis, Caroline works on articles regarding the following topics: finance, cryptocurrency, technology, and politics.